CO2022012616A2 - Compuestos de bencimidazol para el tratamiento de trastornos metabólicos - Google Patents

Compuestos de bencimidazol para el tratamiento de trastornos metabólicos

Info

Publication number
CO2022012616A2
CO2022012616A2 CONC2022/0012616A CO2022012616A CO2022012616A2 CO 2022012616 A2 CO2022012616 A2 CO 2022012616A2 CO 2022012616 A CO2022012616 A CO 2022012616A CO 2022012616 A2 CO2022012616 A2 CO 2022012616A2
Authority
CO
Colombia
Prior art keywords
treatment
metabolic disorders
benzimidazole compounds
formula
prodrugs
Prior art date
Application number
CONC2022/0012616A
Other languages
English (en)
Inventor
Azevedo Hatylas Felype Zaneti De
Junior Marcos Antonio Ferreira
Natanael Dante Segretti
Alessandra Mascarello
Cristiano Ruch Werneck Guimarães
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of CO2022012616A2 publication Critical patent/CO2022012616A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

RESUMEN La presente invención se relaciona en forma amplia con un compuesto de bencimidazol de la Fórmula I para el tratamiento de obesidad, diabetes, enfermedad de hígado graso no alcohólico y esteatohepatitis no alcohólica: Fórmula I o sales, cristales, hidratos, prodrogas, metabolitos o solvatos del mismo farmacéuticamente aceptables.
CONC2022/0012616A 2020-04-15 2022-09-05 Compuestos de bencimidazol para el tratamiento de trastornos metabólicos CO2022012616A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063010128P 2020-04-15 2020-04-15
PCT/BR2021/050158 WO2021207816A1 (en) 2020-04-15 2021-04-15 Benzimidazole compound for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
CO2022012616A2 true CO2022012616A2 (es) 2022-10-21

Family

ID=78083461

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0012616A CO2022012616A2 (es) 2020-04-15 2022-09-05 Compuestos de bencimidazol para el tratamiento de trastornos metabólicos

Country Status (15)

Country Link
US (1) US20230128304A1 (es)
EP (1) EP4136079A4 (es)
JP (1) JP2023522062A (es)
KR (1) KR20230002427A (es)
CN (1) CN115335363A (es)
AR (1) AR121842A1 (es)
AU (1) AU2021256476A1 (es)
CA (1) CA3171746A1 (es)
CL (1) CL2022002821A1 (es)
CO (1) CO2022012616A2 (es)
EC (1) ECSP22078679A (es)
GB (1) GB2609793B (es)
MX (1) MX2022009872A (es)
PE (1) PE20221568A1 (es)
WO (1) WO2021207816A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
AU2003902860A0 (en) * 2003-06-06 2003-06-26 Daicel Chemical Industries, Ltd Benzimidazole compounds
ES2331274B1 (es) * 2007-10-25 2010-10-21 Ferrer Internacional, S.A. Compuesto de indolina.
CA2737694C (en) * 2008-09-26 2013-07-02 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
ES2711808B2 (es) * 2017-11-02 2020-03-13 Univ Granada Uso de un agonista de melatonina para inducir la para inducir adipocitos beige en el tejido adiposo blanco

Also Published As

Publication number Publication date
EP4136079A1 (en) 2023-02-22
AU2021256476A1 (en) 2022-08-25
CL2022002821A1 (es) 2023-04-10
MX2022009872A (es) 2022-08-22
KR20230002427A (ko) 2023-01-05
US20230128304A1 (en) 2023-04-27
PE20221568A1 (es) 2022-10-06
WO2021207816A1 (en) 2021-10-21
GB2609793B (en) 2024-05-08
ECSP22078679A (es) 2022-11-30
AR121842A1 (es) 2022-07-13
GB2609793A (en) 2023-02-15
JP2023522062A (ja) 2023-05-26
GB2609793A8 (en) 2023-03-22
EP4136079A4 (en) 2024-05-15
CN115335363A (zh) 2022-11-11
CA3171746A1 (en) 2021-10-21
GB202215434D0 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
BR112023001195A2 (pt) Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto
CO2018011550A2 (es) Compuestos de pirrolotriazina como inhibidores de tam
DOP2021000148A (es) Compuestos moduladores de fxr (nr1h4)
CU20190080A7 (es) Derivados de isoindolina útiles para tratar la esteatohepatitis no alcohólica y otras enfermedades de curación disfuncional del tejido y fibrosis
AR069165A1 (es) Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
ECSP10010447A (es) Inhibidores de cinasa pim y métodos para su uso
UY32622A (es) Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
CO6321227A2 (es) Moduladores del receptor de la prostaciclina ( pg12) utiles para el tratamiento de transtornos relacionados con este
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
NZ721645A (en) Compounds for use as gpr120 agonists
WO2013038429A3 (en) Novel sglt inhibitors
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
CL2023000154A1 (es) Proceso para preparar tapinarof; compuestos intermediarios; solvato de tapinarof; forma cristalina y composición farmacéutica que la comprende (sol. div. 202001226).
NZ587518A (en) Crystalline form III of (3,5-bis trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3 yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide
CO2021000932A2 (es) Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma
WO2012172566A3 (en) Novel sglt inhibitors
PE20191103A1 (es) Inhibidores de dopamina-b-hidroxilasa
AR087803A1 (es) N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarla
PH12016500838A1 (en) Isoxazolines as therapeutic agents
CO2023006521A2 (es) Forma cristalina iv del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006515A2 (es) Forma cristalina i del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006513A2 (es) Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006517A2 (es) Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
BR112022018515A2 (pt) Terapia de combinação para leucemia mieloide aguda
UY31824A (es) Nuevos compuestos